Research Articles

Pfizer’s New San Diego R&D Hub Accelerates the Next Wave of Cancer Innovation

A state-of-the-art campus designed to turn scientific ambition into breakthroughs for people with cancerFor more than two decades, Pfizer has pushed the boundaries of cancer care, developing medicines that have helped transform treatment for some of the world’s most challenging cancers. That progress continues to fuel an ambition to keep expanding what’s possible – an ambition brought to life in San Diego, where a new state-of-the-art campus has been purpose-built to help advance science and...

April Social Media Round-Up—Trailblazer Cancer Research Grants, World Health Day, and More

April has come to a close and we are barreling towards the summer. Before you head outside to enjoy spring, take a moment to catch up with Pfizer’s social channels, which have been on fire.In April, Pfizer colleagues were honored in the list of 2026 Healthcare Businesswomen’s Association (HBA) Luminaries and Rising Stars, we recognized vaccines’ impact during World Immunization Week, and Pfizer scientists highlighted our research efforts.CEO Albert Bourla recognized Pfizer scientists who were...

Making Progress Against Cancer - From Cancer Research to Prevention and Screening

Advances in cancer care often begin with incremental steps in the lab that, over time, have the power to drive transformative breakthroughs. That’s why scientists are working around the clock to develop potential treatments that could help patients live longer, healthier lives. At Pfizer, Sharsti Sandall is one of those scientists.An executive director in Pfizer’s oncology research division, Sandall leads the antibody drug conjugate (ADC) group, which is a targeted treatment that delivers cancer...

How Biomarker Testing Helped a Lung Cancer Patient Get the Treatment She Needed

Earlier this month, Science Will Win, Pfizer’s award-winning podcast, wrapped up another successful season. Launched in February, season 6 included five episodes, each one focused on a different aspect of the fight against cancer, wrapping with last week’s season finale about AI’s impact on cancer care.All season long, each podcast episode has been accompanied by a full-length video conversation between host Dr. Raven Baxter – a molecular biologist and science educator – and one of her guests...

Ever Wonder How Medicines Get Their Names?

Naming a medicine is more than just a creative exercise. It’s a critical, complicated, and collaborative step in bringing innovative treatments to patients.Some medicine names may sound unfamiliar, but there’s a lot of intention behind every syllable. Long before a treatment reaches patients, its name goes through a careful, highly regulated process designed to help prevent confusion and support safe use in real world healthcare settings.From early lab identifiers to globally recognized generic...

March Social Media Round-Up—2025 Annual Review, World’s Most Ethical Companies, and More

Spring has sprung! At Pfizer, we’re celebrating the changing seasons with exciting updates across our social channels.This March, we received another accolade (Ethisphere recognized Pfizer as one of the World’s Most Ethical Companies for the fifth year in a row), shared new episodes of “Science Will Win” and “What’s In My Lab”, and provided a behind-the-scenes look at our commitment to fighting cancer.We also published our 2025 Annual Review, with opening remarks from CEO Albert Bourla, while...

Science & Innovation

As Colorectal Cancer Rises in Younger Populations, Research and Education is More Important than Ever

At one time, colorectal cancer was a disease associated with older adults. Now, it’s considered the most deadly cancer in people younger than 50.1Even as deaths from the other most common cancers (breast cancer, lung cancer, brain cancer and leukemia) have fallen by 44% over a 30-year-period, according to the American Cancer Society, colorectal cancer deaths have increased 1.1% per year in younger people since 2005.1 It’s a development that’s alarming—and mystifying—healthcare providers and...

February Social Media Round-Up—World Cancer Day, Science Will Win, and More

The groundhog may have predicted six more weeks of winter, but here at Pfizer we’re predicting blue skies ahead as we wrap up another great month.We kicked off February with the launch of season six of “Science Will Win”—Pfizer’s award-winning podcast, announced the launch of The Empowering Women in IBD Leadership program, shared positive results in an ongoing study in patients with metastatic colorectal cancer, and much more.CEO Albert Bourla celebrated World Cancer Day by highlighting the...

Science & Innovation

How Innovative Diagnostics Are Supporting a Potential Approach to C. difficile

When scientists design a new vaccine candidate, they must also identify diagnostic tests that can be used to measure how effective that vaccine is. Those tests are often as unique and innovative as the vaccine candidate itself, says Michael Pride, Pfizer’s Vice President, Bacterial Vaccines.“Just as there’s no one-size-fits-all-pathogens vaccine, every diagnostic test is different, depending on the organism you want to detect,” says Pride.Recently, Pfizer developed and validated a test for use...

Science & Innovation

Behind the Science: A New Path to Tackling Metastatic Breast Cancer

In recent decades, advances in breast cancer treatment have helped to improve health outcomes for many patients, but scientists remain vigilant in their quest to further reduce both the incidence and impact of the disease. Breast cancer is one of the most common cancers in women, with about one in eight women in the United States alone diagnosed during their lifetimes.i Metastatic breast cancer, a more advanced and invasive form of the disease, remains a particularly critical area of unmet need...

January Social Media Round-Up—2026 Strategic Priorities, Clinical Trials, and More

The new year is off to an exciting start here at Pfizer!Already this year, we launched a new episode of “Rewrite the Recipe,” shined a light on the story of a lung cancer patient, The Pfizer Foundation has expanded its Action & Impact initiative, and that’s just the beginning.During a busy trip to Davos, CEO Albert Bourla shared Pfizer’s strategic priorities for the year, sat down with The Wall Street Journal to discuss how the healthcare landscape is changing, and joined industry experts for...

Purpose & Ideals

Hiding in Plain Sight: The Racial Toll of Lyme Disease

Lyme disease is the most common vector-borne illness in the United States.1 Caused by the bacteria Borrelia burgdorferi sensu lato and spread through infected tick bites, it affects an estimated 476,000 Americans each year.1,3Yet the burden of Lyme disease, particularly the experience of a timely diagnosis, isn’t shared equally.Despite its prevalence, the face of Lyme disease in public health data is overwhelmingly white. In the United States, surveillance data shows that over 90% of Lyme...